VLADIMIR ROYTER
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- HANFORD, CA
- NPI
- 1972734119
- Received
- $244,103 in 894 records, 2019 to 2025 ($26,693 general, $217,409 research)
- As principal investigator
- $1,546,569 of research payments to others in 86 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 141 | $13,886 |
| 2024 | General payment | 135 | $2,819 |
| 2023 | General payment | 107 | $1,689 |
| 2022 | General payment | 127 | $2,292 |
| 2021 | General payment | 153 | $2,538 |
| 2021 | Research payment | 26 | $217,409 |
| 2020 | General payment | 105 | $1,583 |
| 2019 | General payment | 100 | $1,883 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 26 | $217,409 |
| Food and Beverage | 834 | $14,518 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 9 | $9,895 |
| Consulting Fee | 1 | $1,525 |
| Travel and Lodging | 3 | $635 |
| Education | 21 | $119 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-12-15 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-15 | LivaNova USA, Inc. | $13 | Food and Beverage | In-kind items and services | VNS Therapy Device, Neurology | 2025 | |
| 2025-12-09 | PFIZER INC. | $3,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-09 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-12-04 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-12-02 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-11-25 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-11-20 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-11-19 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-11-13 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-11-12 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-11-04 | JAZZ PHARMACEUTICALS INC. | $33 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-10-30 | UCB, Inc. | $18 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-10-29 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-10-27 | PFIZER INC. | $1,525 | Consulting Fee | Cash or cash equivalent | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-24 | Eisai Inc. | $30 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-10-23 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-22 | Amgen Inc. | $29 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-17 | UCB, Inc. | $32 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-10-14 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-01 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-23 | Eisai Inc. | $23 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-09-18 | Biogen, Inc. | $25 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-09-17 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-09-16 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-09-11 | Ipsen Biopharmaceuticals, Inc | $25 | Food and Beverage | In-kind items and services | Dysport Drug, Neurology | 2025 | |
| 2025-09-11 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-10 | Alexion Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-09-03 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-02 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-08-28 | Eisai Inc. | $17 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-08-27 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-08-26 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-08-26 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | ABBVIE INC. | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | ARGENX US, INC. | $20 | Food and Beverage | In-kind items and services | VYVGART HYTRULO Drug, Neurology | 2025 | |
| 2025-08-20 | Alexion Pharmaceuticals, Inc. | $26 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-08-19 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-08-19 | MDD US Operations, LLC | $14 | Food and Beverage | In-kind items and services | Qelbree Drug, VILOXAZINE HYDROCHLORIDE | 2025 | |
| 2025-08-15 | ACADIA Pharmaceuticals Inc | $28 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2025 | |
| 2025-08-12 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-08-06 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-29 | Janssen Biotech, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-28 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-07-22 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-17 | Biogen, Inc. | $30 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-07-16 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-07-16 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-15 | NEUROPACE, INC. | $337 | Travel and Lodging | Cash or cash equivalent | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-07-11 | UCB, Inc. | $20 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2025 | |
| 2025-07-10 | ABBVIE INC. | $1,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-07-10 | UCB, Inc. | $0 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2025 | |
| 2025-07-08 | MDD US Operations, LLC | $49 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-07 | NEUROPACE, INC. | $4 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-07-01 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-26 | Vanda Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-06-25 | Eisai Inc. | $22 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-06-23 | ABBVIE INC. | $1,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-19 | ANI Pharmaceuticals, Inc. | $16 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-06-18 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-17 | NEUROPACE, INC. | $8 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-06-16 | UCB, Inc. | $6 | Food and Beverage | In-kind items and services | Fintepla Drug, Neurology | 2025 | |
| 2025-06-12 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-11 | UCB, Inc. | $25 | Food and Beverage | In-kind items and services | Nayzilam Drug, Neurology | 2025 | |
| 2025-06-10 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-06-04 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-05-29 | Eisai Inc. | $26 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-05-28 | NEUROPACE, INC. | $2 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-05-27 | Novartis Pharmaceuticals Corporation | $26 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-05-27 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-05-20 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-05-13 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-05-08 | JAZZ PHARMACEUTICALS INC. | $29 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-05-07 | UCB, Inc. | $30 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2025 | |
| 2025-05-07 | JAZZ PHARMACEUTICALS INC. | $5 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-05-07 | NEUROPACE, INC. | $2 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-04-30 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-04-29 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-04-25 | Neurocrine BioSciences, Inc. | $14 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-23 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-04-23 | NEUROPACE, INC. | $6 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-04-22 | EMD Serono, Inc. | $18 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-21 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-04-16 | JAZZ PHARMACEUTICALS INC. | $30 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-04-14 | LivaNova USA, Inc. | $5 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-04-11 | LivaNova USA, Inc. | $7 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-04-09 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-04-07 | LivaNova USA, Inc. | $9 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-04-03 | Eisai Inc. | $24 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-04-03 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-03-28 | Neurocrine BioSciences, Inc. | $29 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-03-25 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-03-24 | LivaNova USA, Inc. | $5 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-03-24 | NEUROPACE, INC. | $4 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-03-21 | LivaNova USA, Inc. | $22 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-03-21 | Octapharma USA, Inc. | $16 | Food and Beverage | In-kind items and services | PANZYGA Biological, IMMUNOLOGY | 2025 | |
| 2025-03-19 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-18 | JAZZ PHARMACEUTICALS INC. | $25 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-03-17 | LivaNova USA, Inc. | $5 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-03-12 | LivaNova USA, Inc. | $5 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-03-12 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-03-11 | NEUROPACE, INC. | $19 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-03-10 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-03-10 | NEUROPACE, INC. | $4 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-03-07 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-03-05 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-03-04 | Eisai Inc. | $17 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-03-04 | Eisai Inc. | $1 | Food and Beverage | In-kind items and services | Leqembi Drug, Neurology | 2025 | |
| 2025-03-03 | LivaNova USA, Inc. | $9 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-02-21 | JAZZ PHARMACEUTICALS INC. | $23 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2025 | |
| 2025-02-19 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-02-18 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | VUMERITY Drug, Neurology | 2025 | |
| 2025-02-18 | LivaNova USA, Inc. | $9 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-02-18 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-02-13 | Grifols USA, LLC | $21 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2025 | |
| 2025-02-12 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-02-10 | LivaNova USA, Inc. | $8 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-02-05 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-02-03 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-02-03 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-01-29 | LivaNova USA, Inc. | $5 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-01-28 | MDD US Operations, LLC | $46 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2025 | |
| 2025-01-28 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-01-27 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-01-24 | Merz Pharmaceuticals, LLC | $15 | Food and Beverage | In-kind items and services | INBRIJA Drug, Parkinson's Disease | 2025 | |
| 2025-01-22 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-22 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-01-21 | NEUROPACE, INC. | $11 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-01-20 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-01-16 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-15 | LivaNova USA, Inc. | $5 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-01-14 | Vanda Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-01-14 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-13 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2025-01-10 | Alexion Pharmaceuticals, Inc. | $32 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-01-08 | EMD Serono, Inc. | $16 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-01-08 | NEUROPACE, INC. | $7 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2025 | |
| 2025-01-07 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-01-06 | LivaNova USA, Inc. | $6 | Food and Beverage | In-kind items and services | VNS THERAPY SENTIVA MODEL 1000 GENERATOR Device, Neurology | 2025 | |
| 2024-12-18 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-12-18 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-12-18 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-12-12 | Amgen Inc. | $20 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-12-12 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-12-10 | JAZZ PHARMACEUTICALS INC. | $13 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2024 | |
| 2024-12-09 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-12-05 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Nayzilam Drug, Neurology | 2024 | |
| 2024-12-05 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-11-27 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-11-27 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-11-26 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2024 | |
| 2024-11-22 | Biogen, Inc. | $19 | Food and Beverage | In-kind items and services | LEQEMBI Drug, Neurology | 2024 | |
| 2024-11-19 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-11-18 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-11-14 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-11-13 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-11-12 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-11-07 | JAZZ PHARMACEUTICALS INC. | $25 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2024 | |
| 2024-11-05 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-30 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-10-29 | EMD Serono, Inc. | $21 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-10-23 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-17 | JAZZ PHARMACEUTICALS INC. | $18 | Food and Beverage | In-kind items and services | EPIDIOLEX Drug, NEUROLOGY | 2024 | |
| 2024-10-16 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-16 | NEUROPACE, INC. | $7 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-10-15 | Genentech USA, Inc. | $32 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2024-10-12 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-10 | Aucta Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | Motpoly XR Drug, Central Nervous System | 2024 | |
| 2024-10-09 | PFIZER INC. | $22 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-10-09 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-10-08 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-10-04 | UCB, Inc. | $16 | Food and Beverage | In-kind items and services | Briviact Drug, Neurology | 2024 | |
| 2024-10-01 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-09-27 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-09-24 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-09-18 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-09-13 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2024 | |
| 2024-09-11 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-09-09 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-09-09 | NEUROPACE, INC. | $5 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-09-06 | Alexion Pharmaceuticals, Inc. | $28 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-09-04 | Lilly USA, LLC | $27 | Food and Beverage | In-kind items and services | KISUNLA Drug, Neuroscience | 2024 | |
| 2024-09-04 | NEUROPACE, INC. | $4 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-09-03 | SK Life Science, Inc. | $32 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-03 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-08-31 | Alexion Pharmaceuticals, Inc. | $27 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2024 | |
| 2024-08-29 | ANI Pharmaceuticals, Inc. | $25 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2024 | |
| 2024-08-27 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-08-23 | ACADIA Pharmaceuticals Inc | $16 | Food and Beverage | In-kind items and services | NUPLAZID Drug, PARKINSONS DISEASE PSYCHOSIS | 2024 | |
| 2024-08-20 | Grifols USA, LLC | $18 | Food and Beverage | In-kind items and services | Gamunex-C Biological, Immunology and Neurology | 2024 | |
| 2024-08-19 | NEUROPACE, INC. | $4 | Food and Beverage | In-kind items and services | RNS Neurostimulator Kit Device, Epilepsy | 2024 | |
| 2024-08-16 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-08-15 | KYOWA KIRIN, INC. | $18 | Food and Beverage | In-kind items and services | Nourianz Drug, Adenosine A2A Receptors | 2024 | |
| 2024-08-13 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-08-08 | MDD US Operations, LLC | $27 | Food and Beverage | In-kind items and services | Gocovri Drug, AMANTADINE | 2024 | |
| 2024-08-07 | Lundbeck LLC | $22 | Food and Beverage | Cash or cash equivalent | VYEPTI Biological, NEUROLOGY | 2024 | |
| 2024-08-07 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2024 | |
| 2024-08-02 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 |
The latest 200 records of 894.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-01-06 | Novartis Pharmaceuticals Corporation | VLADIMIR ROYTER MD APMC | $102,942 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2024-04-30 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2024 |
| 2024-03-29 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2024 |
| 2024-02-29 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2024 |
| 2024-01-31 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2024 |
| 2024-01-18 | Novartis Pharmaceuticals Corporation | VLADIMIR ROYTER MD APMC | $129,788 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2024 |
| 2023-12-29 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-11-30 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-10-31 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-10-23 | Ares Trading SA | V Royter,MD,APMC | $25 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-10-17 | Ares Trading SA | V Royter,MD,APMC | $25 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-09-29 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-08-31 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-07-31 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-07-30 | Ares Trading SA | V Royter,MD,APMC | $25 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-07-30 | Ares Trading SA | V Royter,MD,APMC | $63 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-05-31 | Ares Trading SA | V Royter,MD,APMC | $85 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2023 |
| 2023-01-10 | Novartis Pharmaceuticals Corporation | VLADIMIR ROYTER MD APMC | $108,720 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2023 |
| 2022-09-06 | Biogen, Inc. | V Royter MD APMC | $2,435 | Plegridy (peginterferon 1a) Real World Effectiveness and Safety Observational Program | 2022 |
| 2022-07-11 | Biogen, Inc. | V Royter MD APMC | $1,507 | A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecf | 2022 |
| 2022-03-01 | Biogen, Inc. | V Royter MD APMC | $5,962 | Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of B | 2022 |
| 2022-02-14 | Novartis Pharmaceuticals Corporation | VLADIMIR ROYTER VLADIMIR ROYTER MD APMC | $206,223 | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY, COMPARING THE EFFICACY AND SAFETY OF REMIBRUTINIB VERSUS | 2022 |
| 2021-12-01 | ABBVIE INC. | VLADIMIR ROYTER MD APMC | $7,644 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sc | 2021 |
| 2021-12-01 | ABBVIE INC. | VLADIMIR ROYTER MD APMC | $7,055 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple | 2021 |
| 2021-11-04 | ABBVIE INC. | VLADIMIR ROYTER MD APMC | $54 | A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sc | 2021 |
| 2021-10-06 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $27 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-08-05 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $1,797 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-08-05 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $1,797 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-06-25 | Biogen, Inc. | V Royter MD APMC | $20,943 | Dimethyl Fumarate (DMF) Observational Study | 2021 |
| 2021-06-03 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $1,836 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-05-06 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $5,015 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-04-21 | Biogen, Inc. | V Royter MD APMC | $3,603 | Plegridy Observational Program | 2021 |
| 2021-04-21 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $3,285 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-03-08 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $3,467 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-02-19 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $2,765 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-02-04 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $6,804 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-01-21 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $8,144 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-01-05 | ABBVIE INC. | ROYTER VLADIMIR V MEDICAL GROUP | $7,654 | A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when | 2021 |
| 2021-01-01 | Biogen, Inc. | V Royter MD APMC | $114,230 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | 2021 |
| 2020-12-04 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $4,595 | M18-918 | 2020 |
| 2020-11-19 | EMD Serono, Inc. | VLADIMIR ROYTER MD APMC | $10,000 | A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib | 2020 |
| 2020-11-19 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $5,203 | M14-397 | 2020 |
| 2020-11-12 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $16,731 | M18-918 | 2020 |
| 2020-10-21 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $9,129 | M14-397 | 2020 |
| 2020-10-06 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $8,429 | M18-918 | 2020 |
| 2020-09-21 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $4,126 | M14-397 | 2020 |
| 2020-09-03 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $7,179 | M18-918 | 2020 |
| 2020-08-20 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $8,629 | M14-397 | 2020 |
| 2020-08-05 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $13,600 | M18-918 | 2020 |
| 2020-07-22 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $10,335 | M14-397 | 2020 |
| 2020-07-07 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $5,994 | M18-918 | 2020 |
| 2020-06-22 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $4,828 | M14-397 | 2020 |
| 2020-06-04 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $7,012 | M18-918 | 2020 |
| 2020-05-21 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $3,910 | M14-397 | 2020 |
| 2020-05-06 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $9,955 | M18-918 | 2020 |
| 2020-04-21 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $9,500 | M14-397 | 2020 |
| 2020-04-03 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $5,657 | M18-918 | 2020 |
| 2020-03-19 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $4,816 | M14-397 | 2020 |
| 2020-03-12 | Biogen, Inc. | V Royter MD APMC | $2,600 | Plegridy Observational Program | 2020 |
| 2020-03-05 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $7,402 | M18-918 | 2020 |
| 2020-02-20 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $3,989 | M14-397 | 2020 |
| 2020-02-05 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $17,687 | M18-918 | 2020 |
| 2020-01-21 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $19,944 | M14-397 | 2020 |
| 2020-01-03 | ABBVIE INC. | VLADIMIR ROYTER MD NEUROLOGIST | $11,901 | M18-918 | 2020 |
| 2020-01-02 | Biogen, Inc. | V Royter MD APMC | $15,716 | Dimethyl Fumarate (DMF) Observational Study | 2020 |
| 2020-01-01 | Biogen, Inc. | V Royter MD APMC | $222,353 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | 2020 |
| 2019-12-19 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $2,965 | M14-397 | 2019 |
| 2019-11-21 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $8,331 | M14-397 | 2019 |
| 2019-11-21 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $18,262 | M18-918 | 2019 |
| 2019-10-21 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $4,395 | M14-397 | 2019 |
| 2019-10-21 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $7,637 | M18-918 | 2019 |
| 2019-09-23 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $3,851 | M14-397 | 2019 |
| 2019-09-23 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $2,464 | M18-918 | 2019 |
| 2019-08-21 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $8,088 | M14-397 | 2019 |
| 2019-07-23 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $1,353 | M18-918 | 2019 |
| 2019-07-23 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $1,218 | M14-397 | 2019 |
| 2019-07-16 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $2,821 | M18-918 | 2019 |
| 2019-07-16 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $4,092 | M14-397 | 2019 |
| 2019-07-01 | Biogen, Inc. | V Royter, MD, APMC | $4,081 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | 2019 |
| 2019-06-20 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $1,111 | M18-918 | 2019 |
| 2019-06-14 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $6,000 | M14-397 | 2019 |
| 2019-06-14 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $3,000 | M18-918 | 2019 |
| 2019-04-22 | ABBVIE INC. | Vladimir Royter, MD Neurologist | $6,000 | M18-918 | 2019 |
| 2019-01-16 | Biogen, Inc. | Dr Vladimir Royter MD Practice | $9,494 | Plegridy Observational Program | 2019 |
| 2019-01-02 | Biogen, Inc. | Dr Vladimir Royter MD Practice | $224,649 | Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | 2019 |
| 2019-01-02 | Biogen, Inc. | Dr Vladimir Royter MD Practice | $20,741 | Dimethyl Fumarate (DMF) Observational Study | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Hanford, CA, county Kings County, CA, state California; placed by its city name.
| Measure | Place (city or town) Hanford, CA | County Kings County, CA | State California |
|---|---|---|---|
| Population B01003 | 59,754 | 153,298 | 39,287,377 |
| Population, 2020 census P1 | 57,990 | 152,486 | 39,538,223 |
| Median age B01002 | 32.5 | 32.5 | 37.9 |
| Under 18 B01001 | 28.7% | 26.8% | 22.0% |
| 65 and over B01001 | 13.3% | 10.8% | 15.7% |
| Households B11001 | 19,518 | 44,052 | 13,548,091 |
| Foreign born B05002 | 14.8% | 19.2% | 27.0% |
| Median household income B19013 | $76,461 | $70,995 | $99,122 |
| Median family income B19113 | $91,980 | $78,609 | $113,346 |
| Per capita income B19301 | $33,147 | $27,306 | $49,513 |
| Poverty rate B17001 | 14.5% | 16.0% | 12.0% |
| Unemployment rate B23025 | 9.5% | 10.8% | 6.6% |
| Civilian labor force B23025 | 26,027 | 60,047 | 20,068,466 |
| Mean commute (minutes) B08013 | 22.6 | 23.0 | 28.7 |
| Bachelor's degree or higher B15003 | 18.1% | 13.6% | 37.1% |
| Housing units B25001 | 20,433 | 46,986 | 14,644,735 |
| Owner-occupied B25003 | 62.1% | 54.2% | 55.9% |
| Renters B25003 | 37.9% | 45.8% | 44.1% |
| Median home value B25077 | $349,400 | $324,300 | $734,700 |
| Median gross rent B25064 | $1,309 | $1,331 | $2,036 |
| White, not Hispanic B03002 | 34.7% | 28.0% | 33.8% |
| Black B03002 | 5.6% | 5.8% | 5.2% |
| Hispanic or Latino B03002 | 51.4% | 58.2% | 40.2% |
| Asian B03002 | 3.9% | 3.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.4% | 0.7% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Hanford, CA.
Comments